Gossamer Bio Investors Class Action Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Should l Buy GOSS?
Source: Globenewswire
- Lawsuit Deadline: Investors in Gossamer Bio must file a lead plaintiff motion by June 1, 2026, to participate in a class action lawsuit concerning securities purchased between June 16, 2025, and February 20, 2026, aimed at recovering losses from the stock price collapse.
- Stock Price Crash: On February 23, 2026, Gossamer disclosed that its Phase 3 PROSERA study failed to meet its primary endpoint, resulting in an 80.3% drop in stock price to $0.42 per share, significantly harming investors and highlighting critical failures in the company's clinical trial.
- False Statements Allegations: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements and failed to disclose adverse facts about its business and prospects, particularly regarding the low-risk characteristics of patients at Latin American sites.
- Legal Implications: Investors who purchased Gossamer securities during the class period may face legal implications; they are advised to contact legal counsel for more information and to participate in the lawsuit to protect their rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GOSS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GOSS
Wall Street analysts forecast GOSS stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.193
Low
10.00
Averages
12.33
High
15.00
Current: 0.193
Low
10.00
Averages
12.33
High
15.00
About GOSS
Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gossamer Bio Launches Exchange Offer for Convertible Notes
- Exchange Offer Initiated: Gossamer Bio has launched an exchange offer for its existing 5.00% Convertible Senior Notes, proposing to exchange them for up to $72 million in new 7.50% Convertible Senior Secured Notes, which is expected to improve the company's capital structure and reduce financial costs.
- High Support from Noteholders: Approximately 75.2% of existing noteholders have signed a transaction support agreement to back the exchange offer, reflecting market confidence in the company's restructuring plan and enhancing the liquidity of the bonds.
- Advantages of New Bond Terms: The new bonds will mature in 2030 with an interest rate of 7.50% and conversion rights, which are expected to attract more investors and enhance the company's financing capabilities and market competitiveness.
- Key Timeline: The exchange offer will expire on June 16, 2026, with an early tender deadline of June 1, 2026, ensuring timely participation will enable the company to successfully complete its debt restructuring and optimize its capital structure.
See More
Multiple Companies Facing Class Action Lawsuits
- Pinterest Lawsuit Overview: Pinterest, Inc. is facing allegations of false statements during the class period from February 7, 2025, to February 12, 2026, which may lead to significant revenue losses and potential restructuring, with a lead plaintiff deadline of May 29, 2026.
- New Era Energy Allegations: New Era Energy & Digital, Inc. is accused of overstating progress on its Texas data center project and engaging in fraudulent schemes from November 6, 2024, to December 29, 2025, with a lead plaintiff deadline of June 1, 2026.
- Gossamer Bio Lawsuit Details: Gossamer Bio, Inc. faces claims of failing to disclose the failure of its clinical trial from June 16, 2025, to February 20, 2026, misleading investors about the company's prospects, with a lead plaintiff deadline of June 1, 2026.
- Medpace Holdings Lawsuit Information: Medpace Holdings, Inc. is accused of making false statements regarding its financial metrics from April 22, 2025, to February 9, 2026, with a lead plaintiff deadline of June 8, 2026, potentially impacting the company's future financing capabilities.
See More
Class Action Lawsuits Filed Against Gossamer Bio and Others
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors that class action lawsuits have been filed against companies like Gossamer Bio, urging affected shareholders to file lead plaintiff motions by the specified deadlines to protect their legal rights.
- Gossamer Bio Allegations: During the period from June 16, 2025, to February 20, 2026, Gossamer Bio is accused of failing to disclose critical issues in its clinical trials, resulting in its Phase 3 PROSERA study not meeting primary endpoints, which negatively impacted investor confidence.
- New Era Energy Allegations: From November 6, 2024, to December 29, 2025, New Era Energy is alleged to have overstated progress on its Texas Critical Data Centers project and engaged in fraudulent schemes, leading to misleading financial results that affected shareholders.
- Medpace Holdings Allegations: During the period from April 22, 2025, to February 9, 2026, Medpace Holdings is accused of overstating its projected book-to-bill ratio for Q4 2025 and failing to adequately assess the impact of cancellations on its business, misleading investors about its operational health.
See More
Reminder for Gossamer Bio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, to apply as lead plaintiffs by June 1, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more victims to participate.
- Lawsuit Background: The lawsuit alleges that Gossamer Bio provided overly optimistic statements while concealing significant adverse facts regarding the study design of its Phase 3 PROSERA study, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and success in the field, which enhances investor confidence in their representation.
See More
Notice of Class Action Lawsuit for Gossamer Bio Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, that they must apply to be lead plaintiff by June 1, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Gossamer made overwhelmingly positive statements while concealing material adverse facts regarding the Phase 3 PROSERA study, particularly concerning the placebo response at Latin American testing sites, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, showcasing its strong track record in this field.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified counsel to protect their interests before the class is certified.
See More
Gossamer Bio Q1 2026 Earnings Call Insights
- Clinical Data Interpretation: CEO Faheem Hasnain highlighted that PROSERA demonstrated a clinically meaningful improvement of 13.3 meters in 6-minute walk distance at week 24, with a p-value of 0.032, which, while statistically significant, did not meet the pre-specified 0.025 threshold, potentially impacting future regulatory approval.
- Cost Control Measures: The company implemented significant layoffs affecting approximately half of its workforce and sharply reduced operating expenses as PROSERA winds down, a strategy aimed at enhancing financial stability and optimizing resource allocation.
- Financial Status Update: As of March 31, 2026, Gossamer reported cash and cash equivalents and marketable securities totaling $99 million, with an expected cash runway extending into the first quarter of 2027, indicating a healthy short-term financial position.
- NDA Submission Plan: The company plans to submit its New Drug Application (NDA) in September 2026 and has scheduled a pre-NDA meeting with the FDA, with potential approval expected in the third quarter of 2027, laying the groundwork for future market launch.
See More
Gossamer Bio Launches Exchange Offer for Convertible Notes
- Exchange Offer Initiated: Gossamer Bio has launched an exchange offer for its existing 5.00% Convertible Senior Notes, proposing to exchange them for up to $72 million in new 7.50% Convertible Senior Secured Notes, which is expected to improve the company's capital structure and reduce financial costs.
- High Support from Noteholders: Approximately 75.2% of existing noteholders have signed a transaction support agreement to back the exchange offer, reflecting market confidence in the company's restructuring plan and enhancing the liquidity of the bonds.
- Advantages of New Bond Terms: The new bonds will mature in 2030 with an interest rate of 7.50% and conversion rights, which are expected to attract more investors and enhance the company's financing capabilities and market competitiveness.
- Key Timeline: The exchange offer will expire on June 16, 2026, with an early tender deadline of June 1, 2026, ensuring timely participation will enable the company to successfully complete its debt restructuring and optimize its capital structure.
See More
Multiple Companies Facing Class Action Lawsuits
- Pinterest Lawsuit Overview: Pinterest, Inc. is facing allegations of false statements during the class period from February 7, 2025, to February 12, 2026, which may lead to significant revenue losses and potential restructuring, with a lead plaintiff deadline of May 29, 2026.
- New Era Energy Allegations: New Era Energy & Digital, Inc. is accused of overstating progress on its Texas data center project and engaging in fraudulent schemes from November 6, 2024, to December 29, 2025, with a lead plaintiff deadline of June 1, 2026.
- Gossamer Bio Lawsuit Details: Gossamer Bio, Inc. faces claims of failing to disclose the failure of its clinical trial from June 16, 2025, to February 20, 2026, misleading investors about the company's prospects, with a lead plaintiff deadline of June 1, 2026.
- Medpace Holdings Lawsuit Information: Medpace Holdings, Inc. is accused of making false statements regarding its financial metrics from April 22, 2025, to February 9, 2026, with a lead plaintiff deadline of June 8, 2026, potentially impacting the company's future financing capabilities.
See More
Class Action Lawsuits Filed Against Gossamer Bio and Others
- Class Action Overview: The Law Offices of Frank R. Cruz remind investors that class action lawsuits have been filed against companies like Gossamer Bio, urging affected shareholders to file lead plaintiff motions by the specified deadlines to protect their legal rights.
- Gossamer Bio Allegations: During the period from June 16, 2025, to February 20, 2026, Gossamer Bio is accused of failing to disclose critical issues in its clinical trials, resulting in its Phase 3 PROSERA study not meeting primary endpoints, which negatively impacted investor confidence.
- New Era Energy Allegations: From November 6, 2024, to December 29, 2025, New Era Energy is alleged to have overstated progress on its Texas Critical Data Centers project and engaged in fraudulent schemes, leading to misleading financial results that affected shareholders.
- Medpace Holdings Allegations: During the period from April 22, 2025, to February 9, 2026, Medpace Holdings is accused of overstating its projected book-to-bill ratio for Q4 2025 and failing to adequately assess the impact of cancellations on its business, misleading investors about its operational health.
See More
Reminder for Gossamer Bio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, to apply as lead plaintiffs by June 1, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more victims to participate.
- Lawsuit Background: The lawsuit alleges that Gossamer Bio provided overly optimistic statements while concealing significant adverse facts regarding the study design of its Phase 3 PROSERA study, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and success in the field, which enhances investor confidence in their representation.
See More
Notice of Class Action Lawsuit for Gossamer Bio Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Gossamer Bio securities between June 16, 2025, and February 20, 2026, that they must apply to be lead plaintiff by June 1, 2026, to participate in the class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that Gossamer made overwhelmingly positive statements while concealing material adverse facts regarding the Phase 3 PROSERA study, particularly concerning the placebo response at Latin American testing sites, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, showcasing its strong track record in this field.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified counsel to protect their interests before the class is certified.
See More
Gossamer Bio Q1 2026 Earnings Call Insights
- Clinical Data Interpretation: CEO Faheem Hasnain highlighted that PROSERA demonstrated a clinically meaningful improvement of 13.3 meters in 6-minute walk distance at week 24, with a p-value of 0.032, which, while statistically significant, did not meet the pre-specified 0.025 threshold, potentially impacting future regulatory approval.
- Cost Control Measures: The company implemented significant layoffs affecting approximately half of its workforce and sharply reduced operating expenses as PROSERA winds down, a strategy aimed at enhancing financial stability and optimizing resource allocation.
- Financial Status Update: As of March 31, 2026, Gossamer reported cash and cash equivalents and marketable securities totaling $99 million, with an expected cash runway extending into the first quarter of 2027, indicating a healthy short-term financial position.
- NDA Submission Plan: The company plans to submit its New Drug Application (NDA) in September 2026 and has scheduled a pre-NDA meeting with the FDA, with potential approval expected in the third quarter of 2027, laying the groundwork for future market launch.
See More
